降压0号对社区高血压患者电解质和血尿酸的影响

The Effects of Compound Antihypertensive Tablets No.0(HTDR) on Serum Potassium,Serum Sodium and Uric Acid in Hypertension Patients in Community

目的评价降压0号长期治疗对社区原发性高血压患者血钾、血钠和血尿酸的影响。方法于2002年3月7日—12月31日选取上海市某社区原发性高血压患者作为研究对象,随访观察社区原发性高血压患者长期服用降压0号后血钾、血钠和血尿酸代谢的改变情况。结果随访满一年的研究对象共计1 162例。长期服用降压0号后血压达标率为79.3%。与基线相比,原发性高血压患者服用降压0号后血钾、血钠水平发生轻度改变,血钾降低0.05 mmol/L、血钠升高1.0 mmol/L;服药后血尿酸水平下降27μmol/L。对血钾、血钠和血尿酸代谢异常情况进行分析发现,服用该药后原发性高血压患者中高钾血症、低钾血症分别下降0.52%和0.60%,高钠血症、低钠血症分别下降0.95%和1.63%,高尿酸血症的比例降低2.18%,以上改变均无统计学意义。结论在社区原发性高血压患者中长期应用降压0号治疗,不会对机体血钾、血钠和血尿酸代谢产生不良影响。

Objective To investigate the long-term influence of Compound antihypertensive Tablets No.O （hydrochlorothiazide 12.Smg,triamterene 12.5 mg,dihydralazine sulfate 12.5 mg,reserpine 0.ling）on serum potassium, serum sodium and uric acid in patients with primary hypertension from a urban community. Methods The long-term community-based follow up study was conducted during March 7 to Dec. 31, 2002 among 2 505 primary hypertension patients in a community located in Shanghai. Changes of serum potassium, serum sodium and uric acid as well as types of metabolic disorder were assessed comparing with baseline. Results A total of 1 162 patients completed a one-year follow-up, of whom 79.3% had reached the BP ＂fulfillment criteria＂. After treated by ＂No.0＂, the serum potassium and the uric acid were decreased, respectively, by 0.05 mmol/L and 27 μmol/L, while the serum sodium was increased by 1.0 mmol/L, compared with those in baseline. The proportion was decreased from 1.12% to 0,60% in hyperkalemia, from 1.89% to 1.29% in hypokalemia, 2.24% to 1.29% in hypernatremia, 3.70% to 2.07% in hyponatremia, and from 21.89% to 19.71% in hyperuricemia, But, there were no significant differences in the changes mentioned above. Conclusion ＂No.0＂ used as an long-term antihypertensive drug, does not appear to have significant adverse effects on serum potassium, serum sodium and uric acid in patients with primary hypertensive in community.